Irked by slow EU rollout, Hungary approves Russia's Sputnik V vaccine against coronavirus
The vaccine, Sputnik V, received a six-month authorisation Wednesday from Hungary’s National Institute of Pharmacy and Nutrition, institute director Matyas Szentivanyi told public television
Budapest: Hungarian authorities have approved a Russian coronavirus vaccine, moving the country closer to becoming the first in the European Union to administer the shot to its population.
The vaccine, Sputnik V, received a six-month authorisation Wednesday from Hungary’s National Institute of Pharmacy and Nutrition, institute director Matyas Szentivanyi told public television. It must be approved by the country’s National Public Health Center, a process that could take several weeks.
Hungary was the first EU country to receive samples of the Russian vaccine in November.
Around 1,34,000 people have been vaccinated with Pfizer-BioNTech and Moderna vaccines in Hungary so far. Hungary’s prime minister, Viktor Orban, has been critical of the speed of the EU’s vaccine rollout and pursued separate agreements with Russia and China in an effort to get more doses to the central European country.
Sputnik V — hailed in August by Russian President Vladimir Putin as the world’s first registered COVID-19 vaccine — has not been approved by the European Medicines Agency, the bloc’s medicines regulator. But member states may negotiate separately with manufacturers not covered by the bloc’s joint procurement programme, and issue temporary emergency use approval to such vaccines.
The Russian vaccine has been approved in six countries including Argentina, Belarus, and Serbia, Hungary’s non-EU neighbour, which began administering Sputnik V this month.
Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply
AstraZeneca vaccine has higher efficacy against COVID-19 with a three-month gap between doses, says Oxford study
The study, published in The Lancet, suggests that the interval between doses can be safely extended to three months than a six-week gap as the first dose can offer up to 76 percent protection during that period
Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval
The vaccine was 66.1% effective in preventing moderate to severe disease and appeared safe, the US Food and Drug Administration said on Wednesday
Ghana's food and drug authority has already authorised the use of the Indian-made vaccines as well as Russia's Sputnik V.